We have applied a sensitive assay to analyze lupus and Sjogren's syndrome autoantibodies in 40 normal sera. Seven of these bound
Introduction
Since systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS)' are diseases acquired by those previously in good health, the characterization of autoimmunity in normals may define how the transition to disease occurs. Autoantibody to Ro/Sjogren's syndrome A antigen (SSA) and La/Sj6gren's syndrome B antigen (SSB) commonly occur in patients with SLE and SS (1) (2) (3) . The presence of anti-Ro/SSA can be associated with several patterns of disease expression, including nephritis (4), complement component C2 deficiency (5) , and photosensitive cutaneous lupus lesions (6) . This antibody has also been found in mothers ofinfants with either cutaneous neonatal lupus or congenital complete heart block (7, 8) , and 0.1% of hospitalized patients (9) , as well as some relatives of patients with autoimmune connective tissue disease (10, 11). 1 . Abbreviations used in this paper: CIE, counterimmunoelectrophoresis; nRNP, nuclear ribonucleoprotein; SS, Sjogren's syndrome; SSA and SSB, Sjogren's syndrome A and B antigens.
Ro/SSA is a RNA-protein complex composed of a 60,000-D peptide noncovalently associated with certain small uridinerich RNAs. In man, there are four RNAs that are associated with the Ro/SSA peptide (12) . The antigenicity is found in at least the peptide since RNAse digestion does not alter its reactivity with anti-Ro/SSA antibody and since the peptide alone reacts with anti-Ro/SSA autoimmune sera in immunoblots (13, 14) . The RNA is termed Y RNA (cytoplasmic RNA) to signify that it is found in the cytoplasm in agreement with early work using autoimmune sera (13, 15) , but more recent workers have claimed that the antigen is found in the nucleus (16) . The role of this RNA-protein in cellular metabolism is not known. Nor is it understood why Ro/SSA is a relatively common autoantigen in man, much less what the factors are that lead this autoantibody in some individuals to be associated with particular disease states or clinical manifestations, while others with anti-Ro/SSA are asymptomatic.
Traditionally, anti-Ro/SSA has been detected by Ouchterlony immunodiffusion using tissue extracts as the antigen source (13) .
With the purification of Ro/SSA, much more sensitive solidphase assays have become feasible (14) . We have evaluated the normal sera with high binding levels to determine if they do indeed have anti-Ro/SSA autoantibody and contrasted their Ro/ SSA binding to that of La/SSB (17) and nuclear ribonucleoprotein (nRNP)(Sm).
Methods
Sample collection. Serum samples from 13 patients with Ro/SSA precipitins and 40 normal donors were collected and stored at -20°C. Normal donors included lab workers, physicians, secretaries, and medical students whose mean age was 32 Antigen purification. Ro/SSA and La/SSB were purified from calf thymus and human spleen extracts as described (14, 17) . Parallel technology was used to purify the nRNP(Sm) antigen using relatively monospecific anti-nRNP IgG to construct an affinity column. Since anti-nRNP purified the U, particle, which contains both nRNP and Sm activities, the resulting preparation has been designated nRNP(Sm).
Enzyme-linked immunosorbent assay (ELISA). A solid-phase assay similar to that described previously (14, 18) F(ab)2 purification. Sera from 13 of the 40 normal donors were collected 18 mo after the initial sampling along with plasma from an antiRo/SSA-positive patient. IgG was isolated from serum by DE52 chromotography (Whatman Chemical Separation, Inc., Clifton, NJ) and digested with pepsin (21) . F(ab')2 fragments were purified by passage through Sephadex G-100 (Pharmacia Fine Chemicals, Piscataway, NJ). The ensuing fractions were coated on a U-vinyl plate and tested for purity with goat anti-human F(ab')2 and Fc conjugated to peroxidase (Cappell Laboratories, Cochranville, PA) using o-phenylenediamine as the indicator substrate. All samples with evidence of Fc contamination were passed through a Staphylococcus protein A Sepharose 4B column (Pharmacia Fine Chemicals), which successfully removed all remaining Fc reactivity.
Anti-Ro/SSA purification. Purified Ro/SSA that showed a single band in an SDS-polyacrylamide gel was coupled by CNBr activation to Sepharose-4B according to the manufacturer's instructions (Pharmacia Fine Chemicals). Plasma from an anti-Ro/SSA-positive normal donor and patient were passed through the affinity column. Bound immunoglobulin was eluted with 3 M MgCl2 and dialyzed into 0.02 M Tris-HCI, pH 7.3. Anti-Ro/SSA activity was evaluated by ELISA as described above and counterimmunoelectrophoresis (CIE) as described by Wasicek and Reichlin (4) .
Autoantibody screen. All available normal sera from the original 40 donors were tested for antinuclear antibodies by indirect immunofluorescence on HEp-2 cells and mouse kidney substrate and for anti-native DNA on Crithidia lucilliae (22) . Anti-single-stranded DNA activity was detected by radioimmunoassay (Farr Technique) and rheumatoid factor was assayed by latex agglutination.
HLA typing. Histocompatability antigens were determined by the microcytotoxicity test using University of California, Los Angeles HLA and DR typing trays (Lamda One; Los Angeles, CA).
Data analysis. Unless otherwise stated, means are presented as the anti log10 of the log10 average of the original data. Fisher's exact test is used to compare categorical data.
Results
Anti-Ro/SSA antibody levels were assayed by ELISA in sera from 13 patients with precipitating levels of anti-Ro/SSA and 40 normal donors. Patients with anti-Ro/SSA precipitins had between 419,000 and 17,309,000 U ofantibody activity specific for Ro/SSA, with an average of 6,022,470 U (Table I) . AntiRo/SSA antibody activity in normal sera was -1,000-fold lower than patient sera and in most of these was not significantly inhibited by purified Ro/SSA. The log average specific binding was 2,484 anti-Ro/SSA units (Table II) . 7 ofthe 40 normal sera (17.5%) consistently had the highest binding activity, which was inhibited by > 50% with purified bovine Ro/SSA in competition assays. These seven sera were carefilly evaluated to determine if this apparent antibody binding activity was Ro/SSA specific or due to nonspecific binding. Human Ro/SSA was purified and used for inhibition experiments to establish whether or not the binding was potentially a true autoantibody as opposed to a heteroantibody against bovine Ro/SSA (Table II) . Each ofthe high binding sera that were inhibited by bovine Ro/SSA were also inhibited by > 50% with the human antigen. Figure 2 . CIE of affinity-purified anti-Ro/SSA from a normal donor (NJ) and an autoimmune patient serum with high levels of anti-Ro/SSA (Pt).
Both precipitate purified Ro/SSA antigen (RoISSA).
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Several of the normal sera were tested by Western blot to demonstrate binding to the 60,000-mol-wt antigenic Ro/SSA protein. Fig. 1 shows the binding of an anti-Ro/SSA-positive patient in lane 1, an anti-Ro/SSA-negative normal serum in lane 2 (donor 1 1), and a normal with elevated anti-Ro/SSA by ELISA in lane 3 (donor 37). The patient and donor 37 sera both bound the 60,000-D Ro/SSA polypeptide.
Sera from 13 ofthe normal donors were reassessed for antiRo/SSA activity after 18 mo. Five ofthe seven control sera with high anti-Ro/SSA continued to display elevated binding activity, while sera from two normal donors no longer bound Ro/SSA. Six of the normal controls that previously failed to bind Ro/ SSA remained negative.
To determine whether the antigen-combining portion of IgG was binding Ro/SSA, F(ab')2 fragments were prepared from normal sera, of which five bound Ro/SSA and six did not. Also included was one Ro/SSA precipitin-positive patient serum. Table III shows anti-Ro/SSA activity by ELISA due to purified F(ab')2 compared with the anti-Ro/SSA activity in whole serum. Four sera had anti-Ro/SSA activity attributable to the F(ab')2 segment of IgG that could be blocked by purified Ro/SSA in competition assays. Donor serum No. 14 failed to satisfy criteria for specific reactivity in the F(ab')2 serum fraction and was not significantly different from the negative control group. Either this serum did not have specific binding when originally tested or the antibody binding was destroyed by pepsin digestion. Indeed, its whole serum reactivity only marginally satisfied the arbitrary criteria for binding to Ro/SSA.
To purify Ro/SSA-specific IgG from normal serum, plasma from normal donor 21 was passed through a Ro/SSA-Sepharose 4B affinity column and the bound immunoglobulin was eluted. Anti-Ro/SSA activity in the eluted Ro/SSA-specific IgG was compared with the anti-Ro/SSA activity in the donor's total, IgG by ELISA. Specific anti-Ro/SSA activity was concentrated 17.7-fold by this procedure relative to whole IgG.
Anti-Ro/SSA purified from normal and patient plasma were then compared in several assay systems. While normal donor 21 whole plasma had failed to precipitate Ro/SSA, the purified anti-Ro/SSA from normal plasma precipitated affinity-purified Ro/SSA in CIE (Fig. 2) . When tested by indirect immunofluorescence on cultured HEp-2 cells, the concentrated normal antiRo/SSA showed a speckled nuclear pattern similar to anti-Ro/ SSA from patient serum (Fig. 3) . Relative binding affinities of purified anti-Ro/SSA from patient and normal plasma were compared in ELISA by determining the concentration of Ro/ SSA that inhibited antibody binding 50%. Anti-Ro/SSA from precipitin-positive patient serum and normal donor 21 had virtually identical relative binding affinities, as shown in Fig. 4 . The relative affinity of the patient's purified anti-Ro/SSA was identical to that of her IgG and was similar to the IgG of five other anti-Ro/SSA containing sera. Thus, we have no evidence that purified and sufficiently concentrated anti-Ro/SSA from normal plasma and anti-Ro/SSA purified from patient plasma are different in any important respect. All normal sera were tested for additional autoantibodies, and two of the seven sera with elevated anti-Ro/SSA demonstrated further serologic abnormalities. Donor 37 was a 25-yrold white female who also bound La/SSB by ELISA (15) . Donor 4, a 22-yr-old white female, displayed several additional links to autoimmunity, including low titer antinuclear antibody, antisingle-strand DNA, intermittently positive rheumatoid factor at Figure 3 . Indirect immunofluorescence of affinity-purified anti-Ro/ SSA from a normal donor (a) and an autoimmune patient serum (b) compared with a normal serum with no detectable anti-Ro/SSA activity (c). Affinity-purified anti-Ro/SSA from a normal donor and an autoimmune patient both displayed a speckled nuclear binding pattern on cultured HEp-2 cells. low titer, and a false-positive VDRL 6 mo before the original serum sampling. This individual had the HLA DR3 haplotype. Ofthe five normal individuals tested whose sera bound Ro/SSA, only this donor had the HLA-DR3 haplotype, while one other was HLA-DR2 positive (Table IV) . There was no apparent association of an HLA antigen with the anti-Ro/SSA found in these normal sera. All 40 normal sera were screened by ELISA for anti-La/ SSB and anti-nRNP(Sm) reactivity. Three sera (7.5%) showed elevated anti-La/SSB levels, which proved to be autoantigen specific as shown previously (15) . None of the 40 normal sera bound nRNP(Sm) (Fig. 5 ).
Discussion
We have established that certain normal individuals have elevated levels of anti-Ro/SSA autoantibody. The antibody can can be demonstrated by binding to purified Ro/SSA in a solidphase ELISA and Western immunoblot as well as precipitation in CIE after concentration. Binding in the anti-Ro/SSA ELISA was inhibited by both human and bovine Ro/SSA in competition assays. The antigen binding was found in the F(ab')2 segment of IgG and therefore can not be attributed to a nonspecific Fc interaction. Anti-Ro/SSA IgG was concentrated 17.7-fold when purified from normal plasma by affinity chromatography.
While 17.5% of normal sera bound Ro/SSA, none ofthe 40 normal sera had anti-nRNP(Sm) activity. In SLE precipitating antibodies to Ro/SSA and La/SSB tend to occur together, while anti-Sm is associated with anti-nRNP (12) . The finding that antiRo/SSA commonly occurs at low levels in the normal population while anti-nRNP(Sm) do not (P = 0.007, Fisher's exact test using data from Fig. 5 ) is consistent with the observed separation of these autoantibodies. This may indicate that different mechanisms ofautoantibody generation are responsible for the presence of these autoantibodies in SLE. Anti-Ro/SSA and anti-La/SSB may occur in SLE by some phenomenon that enhances the production of antibody already present in some normal individuals. On the other hand, the initiation ofanti-nRNP or anti-Sm would apparently require some primary immune response, as these autoantibodies are rare or absent in the normal population.
The presence of autoantibodies in low frequencies among normal subjects has been reported from time to time, including antinuclear antibodies and rheumatoid factor (23, 24) . When autoantibodies were assessed in normal females according to age, the highest incidence occurred in the older age group (24). Less frequently precipitating levels of autoantibody to ribonuclear proteins have been documented (9, 24, 25) . The highest incidence of autoantibody in normal individuals has been reported in mothers of neonatal lupus infants. More than 80% of these asymptomatic mothers have anti-Ro/SSA and/or antiLa/SSB with no clinical manifestations of autoimmune disease (7, 8) . These mothers, however, seem to be at risk for future development of the clinical symptoms of connective tissue disease (26 (27) , and had been associated with anti-Ro/SSA precipitins in lupus (28) .
An increased prevalence of SLE in females over males has been documented (29) , as well as an increase in autoreactivity among the elderly (24). 24 females and 16 males participated in this study, which is equal to the ratio of anti-Ro/SSA-positive females and males, 3:2 (Table IV) . When the average age of our normal donors was assessed, the anti-Ro/SSA-positive donor's mean age was 32.4 yr, which was not significantly different from the group average of 32.7 yr. Thus, in our study, neither sex nor age accounted for the high incidence of Ro/SSA binding in the normal sera. When the mean ages of anti-Ro/SSA-positive females versus males were considered, however, the average female age was 24 yr, compared with the average age of males, which was 45 yr. This becomes interesting in light of the observation that the largest proportion of female SLE patients have disease onset at a young age (29 
